Mechanisms of Resistance to Anti-Angiogenic Therapy and Development of Third-Generation Anti-Angiogenic Drug Candidates — Sonja Loges (2010) | RDL Network
The concept of inhibiting tumor neovessels has taken the hurdle from the bench to the bedside and now represents an extra pillar of anticancer treatment. So far, anti-angiogenic therapy prolongs survival in the order of months in some settings while failing to induce a survival benefit in others, in part because of intrinsic refractoriness or evasive escape. This review provides an update on recent mechanisms via which tumor and stromal cells induce resistance and discusses recent evolutions in the (pre)clinical development of novel third-generation anti-angiogenic agents to overcome this problem.
Helena Cornellà, Victoria Tovar, Yujin Hoshida, Augusto Villanueva, Sara Toffanin, Daniela Sia, Judit Peix, Anja Lachenmayer, Clara Alsinet, Manel Solé, Myron Schwartz, Vincenzo Mazzaferro, Jordi Bruix, Josep M. Llovet
Marina Ruiz de Galarreta, Erin Bresnahan, Pedro Molina-Sánchez, Katherine E. Lindblad, Bárbara Maier, Daniela Sia, Marc Puigvehí, Verónica Miguela, María Casanova-Acebes, Maxime Dhainaut, Carlos Villacorta-Martín, Aatur D. Singhi, Akshata Moghe, Johann von Felden, Lauren Tal Grinspan, Shuang Wang, Alice O. Kamphorst, Satdarshan P. Monga, Brian D. Brown, Augusto Villanueva, Josep M. Llovet, Miriam Mérad, Amaia Lujambio
Discussion(0)
No comments yet. Be the first to comment.